Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70370 ↗At a glance
Klinische Studie (Phase II) in Clinical Transplantation, 2025. Written by Britta S Bürker and 5 co-authors. Institution: Norwegian National Unit for Sensory Loss and Mental Health, Oslo University Hospital, Oslo, Norway. Major MEDLINE topics: Anemia, Iron-Deficiency, Cognition, Cognitive Dysfunction, Dietary Supplements. 24 references.
Abstract (original language)
Background
Cognitive dysfunction after successful heart transplantation (HTx) is not uncommon. Lower hemoglobin levels have previously been associated with cognitive dysfunction in heart transplant recipients (HTx recipients). In a randomized, placebo‐controlled, double‐blind treatment trial, we assessed as a pre‐specified secondary outcome whether a single intravenous iron supplement for iron deficiency in HTx recipients resulted in changes in cognitive function after 6 months.
Methods
In the “Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients” (IronIC) trial, we assessed cognitive function at baseline and at 6‐month follow‐up with the following tests of the Cambridge Neuropsychological Test Automated Battery: Reaction Time, Paired Associates Learning, and Spatial Working Memory. Of 94 participants with cognitive data at baseline and follow‐up, 49 were randomized to the single intravenous iron supplement, while 45 received placebo.
Results
Raw score changes from baseline to follow‐up did not differ statistically significantly between study groups (two measures of each test analyzed). In the total sample, 27%–44% of participants performed at baseline at least one standard deviation below the normative mean on measures of memory and working memory/executive functions. Exploratory analyses indicated that performance on measures of memory might decrease more than expected with increasing age.
Conclusion
A single intravenous iron supplement for iron deficiency in HTx recipients did not result in statistically significant cognitive changes after 6 months. The group as a whole performed approximately half a standard deviation below the normative mean on measures of memory and working memory/executive functions. Regular cognitive screening after HTx is recommended. Clinical Trial Registration Trial Registration: ClinicalTrials.gov identifier: NCT03662789
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Norwegian National Unit for Sensory Loss and Mental Health, Oslo University Hospital, Oslo, Norway.
- Department of Cardiology, Oslo University Hospital - Rikshospitalet, Oslo, Norway.
- Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
- Department of Psychology, University of Oslo, Oslo, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
ORCID profiles: Britta S Bürker, Kristine V Brautaset Englund, Lars Gullestad
Cite
APA
Bürker, B. S., Brautaset Englund, K. V., Myrdal Østby, C., Andersson, S., Gullestad, L., & Broch, K. (2025). Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial. Clinical Transplantation. https://doi.org/10.1111/ctr.70370
Vancouver
Bürker BS, Brautaset Englund KV, Myrdal Østby C, Andersson S, Gullestad L, Broch K. Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial. Clinical Transplantation. 2025. doi:10.1111/ctr.70370
BibTeX
@article{Brker2025,
author = {Bürker, Britta S and Brautaset Englund, Kristine V and Myrdal Østby, Charlotte and Andersson, Stein and Gullestad, Lars and Broch, Kaspar},
title = {Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70370}
}
EUVIMED